Results 1 to 10 of about 69,107 (331)

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid [PDF]

Frontiers in Immunology, 2019
Bullous pemphigoid (BP) is an organ-specific autoantibody-mediated blistering skin disease that mainly affects the elderly. Typical clinical features include the widespread blisters, often preceded by and/or associated with itchy urticarial or eczema ...
Kaisa Tasanen, Outi Varpuluoma, Wataru Nishie   +2 more
doaj   +4 more sources

Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation [PDF]

Acta Dermato-Venereologica
Psoriatic disease, encompassing psoriasis and -psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus.
Chih-Tsung Hung, Chi-Hsiang Chung, Tsu-Hsuan Weng, Chun-Teng Tsai, Wu-Chien Chien, Yung-Lung Chang   +5 more
doaj   +2 more sources

Increased Dipeptidyl Peptidase-4 Promotes Adipose Inflammation and Dysfunction in Mice Under Chronic Stress. [PDF]

FASEB J
Zhang M, Wang H, Li X, Shu S, Piao J, Yue X, Zhao S, Li M, Jin X, Nan Y, Cheng XW.   +10 more
europepmc   +3 more sources

Novel Dipeptidyl Peptidase-4–Inhibiting Peptide Derived From β-Lactoglobulin

Journal of Pharmacological Sciences, 2011
.: Trypsin-treated β-lactoglobulin significantly decreased the glucose level after an oral glucose tolerance test using mice. We performed the present study to identify the active peptide inhibiting dipeptidyl peptidase-4 from trypsin-treated β ...
Masayuki Uchida, Yukio Ohshiba, Orie Mogami   +2 more
doaj   +3 more sources

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors

Терапевтический архив, 2013
The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.
A S Ametov, L L Kamynina
doaj   +2 more sources

SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS [PDF]

Trakia Journal of Sciences, 2023
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and ...
M. Ganeva
doaj   +1 more source

Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism. [PDF]

PLoS ONE, 2016
Trelagliptin (SYR-472), a novel dipeptidyl peptidase-4 inhibitor, shows sustained efficacy by once-weekly dosing in type 2 diabetes patients. In this study, we characterized in vitro properties of trelagliptin, which exhibited approximately 4- and 12 ...
Charles E Grimshaw, Andy Jennings, Ruhi Kamran, Hikaru Ueno, Nobuhiro Nishigaki, Takuo Kosaka, Akiyoshi Tani, Hiroki Sano, Yoshinobu Kinugawa, Emiko Koumura, Lihong Shi, Koji Takeuchi   +11 more
doaj   +1 more source

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes [PDF]

Diabetes & Metabolism Journal, 2013
BackgroundThe aims of this study are to investigate the glycemic efficacy and predictive parameters of vildagliptin therapy in Korean subjects with type 2 diabetes.MethodsIn this retrospective study, we retrieved data for subjects who were on twice-daily
Jin-Sun Chang, Juyoung Shin, Hun-Sung Kim, Kyung-Hee Kim, Jeong-Ah Shin, Kun-Ho Yoon, Bong-Yun Cha, Ho-Young Son, Jae-Hyoung Cho   +8 more
doaj   +1 more source

Dynamics of total volume of pancreatic α‐ and β ‐cells under the influence sulfonylureas and their combination with dipeptidyl peptidase‐4 inhibitors

Endocrinology, Diabetes & Metabolism, 2021
Objective Sulfonylureas and dipeptidyl peptidase‐4 inhibitors have a multidirectional effect on pancreatic cells. We aimed to evaluate the effects of these drugs on β‐ and α‐cells in rats aged 12 months with type 2 diabetes mellitus when administered in ...
Tuchina Taisiia Pavlovna, Skotnikova Kseniia Petrovna, Vtorushina Anna Anatolievna, Uskov Ivan Sergeyevich, Rogoza Olga Vladimirovna, Grozov Roman Viktorovich, Babenko Alina Yurievna, Galagudza Mikhail Mikhailovich   +7 more
doaj   +1 more source

Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database. [PDF]

Sci Rep
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +3 more sources